Oxford, UK – 09 February 2011. OGT, provider of innovative genetics and biomarker solutions to advance molecular medicine, has expanded its CytoSure® product range to include high-throughput genomic DNA labelling kits and sample tracking spike-ins. These new products will further streamline workflow and minimise sample tracking errors when performing array comparative genomic hybridisation (aCGH).
The new CytoSure HT Genomic DNA Labelling Kit makes it possible to simultaneously label up to 96 samples using a 96-well plate format, boosting cost-effectiveness, increasing processing speed and facilitating automated sample handling. The unique formulation and mastermix-based approach maximises signal-to-noise ratio and reduces sample-to-sample variation, facilitating the confident detection of even the smallest aberrations.
CytoSure ISCA Sample Tracking Spike-ins ensure that any potential sample mix-up during array processing can be easily identified, safeguarding against mistakes and maximising data confidence. When used in combination with CytoSure ISCA arrays and OGT’s powerful CytoSure Interpret Software, these new products make it easy to correlate individual data sets with sample origin.
Ruth Burton, OGT’s Product Manager Clinical Solutions, commented: “We regularly invite our customers to provide input into future product development in order to better meet their requirements. Developed in response to recent feedback, these new products provide efficient DNA labelling and dedicated sample tracking, maximising precision in the aCGH workflow.”
The new CytoSure HT Genomic DNA Labelling Kit and ISCA Sample Tracking Spike-ins expand the CytoSure range of products and services, to further broaden OGT’s cutting-edge cytogenetic solutions and provide market-leading accuracy, reliability and ease-of-use.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read